Away from the football fields and media attention, a Pittsburgh company has developed medicine it believes can treat the degenerative brain disease chronic traumatic encephalopathy, or CTE.

Noveome Biotherapeutics has created a nasal spray, to be administered during clinical trials later this year, which could treat CTE and ailments such as optic nerve damage.

CTE, which was discovered by neuropathologist Bennet Omalu while working as a pathologist in the Allegheny County coroner’s office, is a debilitating disease that creates behavioral issues, damages a person’s ability to think and leaves them prone to mood swings. A considerable number of those found to have been afflicted by the illness have committed suicide.

CTE is a disease largely defined by its mystery. At this point, a definitive CTE diagnosis can be made only posthumously and there are no approved treatments for it.

Advertise with us

Because of these factors, Noveome’s medicine is likely to face challenges at its clinical trials. It may not be as effective as the company had hoped, or perhaps it will be found that prescribing the medicine to someone who does not actually have CTE could have adverse effects.

Regardless of the outcome, it is a promising and important development that medical researchers are making substantive leaps in their ability to understand and treat CTE.

CTE affects the games we all enjoy, but, of far greater consequence, it also has a direct and painful impact on the lives of those who suffer from it. It is not satisfactory to suspect someone may have CTE and then write that person off as a lost cause. It is important that medical researchers continue to work to find causes, ways to diagnose the disease and ways to treat it.

Noveome should be commended for its progress, but let’s not let it stop here.